Your browser doesn't support javascript.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Ewer, Katie J; Barrett, Jordan R; Belij-Rammerstorfer, Sandra; Sharpe, Hannah; Makinson, Rebecca; Morter, Richard; Flaxman, Amy; Wright, Daniel; Bellamy, Duncan; Bittaye, Mustapha; Dold, Christina; Provine, Nicholas M; Aboagye, Jeremy; Fowler, Jamie; Silk, Sarah E; Alderson, Jennifer; Aley, Parvinder K; Angus, Brian; Berrie, Eleanor; Bibi, Sagida; Cicconi, Paola; Clutterbuck, Elizabeth A; Chelysheva, Irina; Folegatti, Pedro M; Fuskova, Michelle; Green, Catherine M; Jenkin, Daniel; Kerridge, Simon; Lawrie, Alison; Minassian, Angela M; Moore, Maria; Mujadidi, Yama; Plested, Emma; Poulton, Ian; Ramasamy, Maheshi N; Robinson, Hannah; Song, Rinn; Snape, Matthew D; Tarrant, Richard; Voysey, Merryn; Watson, Marion E E; Douglas, Alexander D; Hill, Adrian V S; Gilbert, Sarah C; Pollard, Andrew J; Lambe, Teresa.
  • Ewer KJ; The Jenner Institute, University of Oxford, Oxford, UK. katie.ewer@ndm.ox.ac.uk.
  • Barrett JR; The Jenner Institute, University of Oxford, Oxford, UK.
  • Belij-Rammerstorfer S; The Jenner Institute, University of Oxford, Oxford, UK.
  • Sharpe H; The Jenner Institute, University of Oxford, Oxford, UK.
  • Makinson R; The Jenner Institute, University of Oxford, Oxford, UK.
  • Morter R; The Jenner Institute, University of Oxford, Oxford, UK.
  • Flaxman A; The Jenner Institute, University of Oxford, Oxford, UK.
  • Wright D; The Jenner Institute, University of Oxford, Oxford, UK.
  • Bellamy D; The Jenner Institute, University of Oxford, Oxford, UK.
  • Bittaye M; The Jenner Institute, University of Oxford, Oxford, UK.
  • Dold C; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Provine NM; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Aboagye J; The Jenner Institute, University of Oxford, Oxford, UK.
  • Fowler J; The Jenner Institute, University of Oxford, Oxford, UK.
  • Silk SE; The Jenner Institute, University of Oxford, Oxford, UK.
  • Alderson J; The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
  • Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Angus B; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Berrie E; Clinical Biomanufacturing Facility, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bibi S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Cicconi P; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Chelysheva I; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Folegatti PM; The Jenner Institute, University of Oxford, Oxford, UK.
  • Fuskova M; The Jenner Institute, University of Oxford, Oxford, UK.
  • Green CM; Clinical Biomanufacturing Facility, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Jenkin D; The Jenner Institute, University of Oxford, Oxford, UK.
  • Kerridge S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Lawrie A; The Jenner Institute, University of Oxford, Oxford, UK.
  • Minassian AM; The Jenner Institute, University of Oxford, Oxford, UK.
  • Moore M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Mujadidi Y; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Plested E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Poulton I; The Jenner Institute, University of Oxford, Oxford, UK.
  • Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Song R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Tarrant R; Clinical Biomanufacturing Facility, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Voysey M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Watson MEE; The Jenner Institute, University of Oxford, Oxford, UK.
  • Douglas AD; The Jenner Institute, University of Oxford, Oxford, UK.
  • Hill AVS; The Jenner Institute, University of Oxford, Oxford, UK.
  • Gilbert SC; The Jenner Institute, University of Oxford, Oxford, UK.
  • Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Lambe T; The Jenner Institute, University of Oxford, Oxford, UK. Teresa.lambe@ndm.ox.ac.uk.
Nat Med ; 27(2): 270-278, 2021 02.
Article in English | MEDLINE | ID: covidwho-1065916
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed1. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses2 and might reduce the potential for disease enhancement3. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection4. Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. 5,6). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)7 given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8+ T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / COVID-19 Vaccines / Antibody Formation Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2021 Document Type: Article Affiliation country: S41591-020-01194-5

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / COVID-19 Vaccines / Antibody Formation Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2021 Document Type: Article Affiliation country: S41591-020-01194-5